Endotracheal Tubes to Prevent Ventilator-Associated Pneumonia (PreVent2)
Primary Purpose
Ventilator-acquired Pneumonia
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
EVAC-PU-ETT
PVC-ETT
Sponsored by
About this trial
This is an interventional prevention trial for Ventilator-acquired Pneumonia focused on measuring Pneumonia, Endotracheal intubation
Eligibility Criteria
Inclusion Criteria:
- ≥18 years of age
- Requiring emergency endotracheal intubation in the ED or in-hospital for acute respiratory distress or failure
- A study intubation kit containing the study ID number must have been used for the emergency intubation
- Admitted to the ICU and receiving mechanical ventilation
Exclusion Criteria:
- Patients electively intubated in the operating room whether or not they require subsequent ICU admission
- Use of a non-study designated intubation kit (such as nasal intubation, tracheotomy, intubation occurring at a location not supplied with the study intubation kits)
- Patients with permanent tracheostomy
- Protected populations including children (age <18 years), pregnant women, or prisoners
- Evidence of unwillingness to participate in a research study as documented in the patient's electronic health record, or at the time of intubation if there is opportunity to read the opt-out script.
Sites / Locations
- Yale New Haven Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
PVC-ETT
EVAC-PU-ETT
Arm Description
Polyvinylchloride endotracheal tube
Continuous aspiration of subglottic secretions with polyurethane cuff endotracheal tube
Outcomes
Primary Outcome Measures
Quality of life
36-item Short-Form General Health Survey (Scores range from 0 - 100; Lower scores = more disability, higher scores = less disability)
Cognitive function
Proportion of patients cognitively impaired, assessed by the National Alzheimer Coordinating Center's Uniform Data Set
Secondary Outcome Measures
Airway related complications
Device-related adverse events
Full Information
NCT ID
NCT03705286
First Posted
October 3, 2018
Last Updated
May 31, 2023
Sponsor
Yale University
Collaborators
National Heart, Lung, and Blood Institute (NHLBI), Oregon Health and Science University
1. Study Identification
Unique Protocol Identification Number
NCT03705286
Brief Title
Endotracheal Tubes to Prevent Ventilator-Associated Pneumonia
Acronym
PreVent2
Official Title
Randomized Trial of Endotracheal Tubes to Prevent Ventilator-Associated Pneumonia - PreVent 2 Study
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Completed
Study Start Date
May 6, 2019 (Actual)
Primary Completion Date
February 23, 2023 (Actual)
Study Completion Date
February 23, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Yale University
Collaborators
National Heart, Lung, and Blood Institute (NHLBI), Oregon Health and Science University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Researchers are looking at two different types of breathing tubes to see if one is better than the other at preventing pneumonia. One of the tubes has a design features to prevent leakage of fluids from the mouth and the back of the throat into the lower airways and lungs. This is important since leakage of small amounts of fluid into the lungs may lead to pneumonia. The other tube is the standard tube used at most hospitals.
The hypothesis is that the use of a breathing tube that reduces fluid leakage into the lungs will reduce the risk of developing pneumonia and improve quality of life and cognitive function, compared to the standard tube. The study will also look at the safety of the modified breathing tube, compared to the standard tube.
Detailed Description
The proposed study will be a randomized, controlled trial, conducted under Exception From Informed Consent (EFIC), comparing patients who undergo emergency tracheal intubation with one of two different endotracheal tubes (ETTs), one of which is designed to prevent ventilator-associated pneumonia (VAP): 1) An ETT fitted with a lumen to allow continuous aspiration of subglottic secretions and made with a polyurethane cuff (EVAC-PU-ETT); and 2) A standard ETT with a polyvinylchloride cuff (PVC-ETT). Approximately 1,074 adult patients requiring endotracheal intubation in the ED or hospital for acute respiratory distress or failure will be randomly assigned in an equal fashion to be intubated with one of the two ETTs (537 patients in each group). Because endotracheal intubation is performed in an emergency setting, the unit of randomization will be the intubation kits containing, in a concealed manner, one of the two types of ETT. The intubation kits are placed in areas where emergency intubation teams receive their intubation equipment supplies, primarily in the ICUs and in the emergency department. The study is designed to allow all patients requiring emergency intubation to be potentially eligible for enrollment to ensure the applicability of the study findings to a generalizable setting of patients receiving emergency intubation outside the operating room.
The trial primary aim is to determine if EVAC-PU-ETT is as safe as PVC-ETT and if long-term patient quality of life and cognitive function are better in PU-CASS-ETT, compared with PVC-ETT. The investigators will also monitor any device-related adverse events. Additional secondary endpoints include the incidence of infection-related ventilator associated conditions (IVAC) and ventilator associated events (VAEs), as defined by the Center for Disease Control, respiratory antibiotics use, incidence of "clinical" VAP, 28-day ventilator-free days, mean daily Sequential Organ Failure Assessment (SOFA) score, length of ICU and hospital stay, and mortality up to six months will serve to evaluate other clinical meaningful consequences resulting from the occurrence of VAP. Furthermore, the study will perform economic evaluation (cost-consequence approach) of quality of life, healthcare resource utilization and cost for hospitals. Primary and secondary endpoints will be compared between the PU-CASS-ETT and PVC-ETT groups, using an intention-to-treat approach.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ventilator-acquired Pneumonia
Keywords
Pneumonia, Endotracheal intubation
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
1074 (Actual)
8. Arms, Groups, and Interventions
Arm Title
PVC-ETT
Arm Type
Active Comparator
Arm Description
Polyvinylchloride endotracheal tube
Arm Title
EVAC-PU-ETT
Arm Type
Experimental
Arm Description
Continuous aspiration of subglottic secretions with polyurethane cuff endotracheal tube
Intervention Type
Device
Intervention Name(s)
EVAC-PU-ETT
Other Intervention Name(s)
Shiley™ Evac Oral Tracheal Tube, SealGuard™, Murphy Eye
Intervention Description
Placement of a EVAC-PU-ETT in the setting of emergent intubation.
Intervention Type
Device
Intervention Name(s)
PVC-ETT
Other Intervention Name(s)
Shiley™ Cuffed Basic Endotracheal Tube
Intervention Description
Placement of a PVC-ETT in the setting of emergent intubation.
Primary Outcome Measure Information:
Title
Quality of life
Description
36-item Short-Form General Health Survey (Scores range from 0 - 100; Lower scores = more disability, higher scores = less disability)
Time Frame
6 months
Title
Cognitive function
Description
Proportion of patients cognitively impaired, assessed by the National Alzheimer Coordinating Center's Uniform Data Set
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Airway related complications
Description
Device-related adverse events
Time Frame
6 months
Other Pre-specified Outcome Measures:
Title
Infection Related Ventilator-Associated Complications (IVACs)
Description
Center for Disease Control defined IVACs
Time Frame
Up to 28 days
Title
Ventilator-Associated Events (VAEs)
Description
Center for Disease Control defined VAEs
Time Frame
Up to 28 days
Title
Healthcare costs
Description
Healthcare resource utilization
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
≥18 years of age
Requiring emergency endotracheal intubation in the ED or in-hospital for acute respiratory distress or failure
A study intubation kit containing the study ID number must have been used for the emergency intubation
Admitted to the ICU and receiving mechanical ventilation
Exclusion Criteria:
Patients electively intubated in the operating room whether or not they require subsequent ICU admission
Use of a non-study designated intubation kit (such as nasal intubation, tracheotomy, intubation occurring at a location not supplied with the study intubation kits)
Patients with permanent tracheostomy
Protected populations including children (age <18 years), pregnant women, or prisoners
Evidence of unwillingness to participate in a research study as documented in the patient's electronic health record, or at the time of intubation if there is opportunity to read the opt-out script.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Miriam M Treggiari, MD, PhD, MPH
Organizational Affiliation
Yale University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Yale New Haven Hospital
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06511
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Endotracheal Tubes to Prevent Ventilator-Associated Pneumonia
We'll reach out to this number within 24 hrs